Ding, Jiarui http://orcid.org/0000-0003-3670-7764
Garber, John J. http://orcid.org/0009-0007-8064-2829
Uchida, Amiko
Lefkovith, Ariel
Carter, Grace T. http://orcid.org/0000-0001-5514-4237
Vimalathas, Praveen
Canha, Lauren
Dougan, Michael
Staller, Kyle
Yarze, Joseph
Delorey, Toni M. http://orcid.org/0000-0001-6614-3803
Rozenblatt-Rosen, Orit http://orcid.org/0000-0001-6313-3570
Ashenberg, Orr
Graham, Daniel B. http://orcid.org/0000-0002-8403-8115
Deguine, Jacques http://orcid.org/0000-0001-9218-3040
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Xavier, Ramnik J. http://orcid.org/0000-0002-5630-5167
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30 DK043351)
Article History
Received: 8 September 2023
Accepted: 9 April 2024
First Online: 18 April 2024
Competing interests
: R.J.X. is a co-founder of Jnana Therapeutics and Celsius Therapeutics, a scientific advisory board member at Nestlé, and board director at MoonLake Immunotherapeutics; these organizations had no roles in this study. A.R. is a founder and equity holder of Celsius Therapeutics, is an equity holder in Immunitas Therapeutics, and, until 31 August 2020, was a scientific advisory board member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov, and ThermoFisher Scientific. Since 1 August 2020, A.R. has been an employee of Genentech, a member of the Roche Group, with equity in Roche. K.S. is a consultant to Sanofi. All other authors declare no competing interests.